Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/18/2026

1. SPY
2. EYPT
3. NVDA
4. ARGX
5. USO
6. AWK
7. TSLA
8. HD
9. GNK
10. MU

Go back to Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
(NYSE: ANRO) Delayed: 33.60 --0 (-0%)
Previous Close $33.60    52 Week High $ 
Open $33.60    52 Week Low $ 
Day High $33.60    P/E N/A 
Day Low $33.60    EPS $ 
Volume 4